Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Dalbavancin (Dalvance) Peptide
Long-acting lipoglycopeptide for skin and soft tissue infections.
What is Dalbavancin (Dalvance)?
Dalbavancin (Dalvance) is a lipoglycopeptide · infectious disease peptide studied for acute bacterial skin and skin structure infections (absssi) and s. aureus bacteremia (investigational). Below is an educational overview of Dalbavancin (Dalvance) peptide benefits, mechanism, common research protocols, dosage references, and known side effects.
Plain-Language Label Highlights
Brand names: Dalvance
Acute bacterial skin and skin structure infections (ABSSSI) including MRSA.
An IV antibiotic given as one or two doses — useful when daily IV therapy isn't practical.
- •Nausea
- •Headache
- •Diarrhea
- •Liver enzyme elevations
- •Infusion reactions (slow infusion)
- •C. difficile colitis
- •Known hypersensitivity to glycopeptide antibiotics
Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.
Dalbavancin (Dalvance) Mechanism of Action
Semi-synthetic lipoglycopeptide that binds D-Ala-D-Ala, inhibiting Gram-positive cell wall synthesis; long terminal half-life supports single- or two-dose courses.
Dalbavancin (Dalvance) Research Areas & Benefits
Dalbavancin (Dalvance) Dosage & Common Research Protocols
1500 mg IV single dose, or 1000 mg then 500 mg one week later.
Protocols summarized for educational reference from published research. Not dosing guidance.
Dalbavancin (Dalvance) Studies & Cited Research
DISCOVER 1 & 2 trials
Non-inferior to vancomycin/linezolid for ABSSSI with simpler dosing.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
Citations are linked to PubMed, Google Scholar, and Crossref searches so you can verify the source independently. All references are reviewed during our editorial passes (last reviewed June 1, 2026).
Dalbavancin (Dalvance) Side Effects & Safety Considerations
- •FDA-approved.
- •Allows outpatient single-dose treatment.
Explore more peptides
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.